If you are considering use (or marketing) of such a product: do so with realistic expectations , full transparency, and emphasis on safety + monitoring rather than over-hyped claims
(2000) J.Pharmacol.Exp.Ther
The MHRA has approved various GLP-1 medications for type 2 diabetes and, more recently, for weight management in specific circumstances
By injecting AAV--syn into the brains of animals, it induces the overexpression of -syn (Kelly et al., 2021), thereby simulating the pathological features of human neurodegenerative diseases
Rare but serious gastrointestinal complications have been reported in post-marketing surveillance, including: Acute pancreatitis : If suspected, the GLP-1 agonist should be stopped immediately and not restarted if pancreatitis is confirmed Severe gastroparesis : Rare post-marketing reports of severe delayed gastric emptying Intestinal obstruction : Very rare cases reported in post-marketing surveillance Patients should be advised to seek urgent medical help via NHS 111, A&E or 999 as appropriate if they experience severe or persistent abdominal pain, persistent vomiting, abdominal distension, inability to pass stool or gas, or bloody diarrhoea whilst taking GLP-1 agonists
Not only does it support red blood cell production, but it also helps energy levels and overall well-being